Skip to main content
Premium Trial:

Request an Annual Quote

Luminex and Genospectra

Premium

Luminex, Genospectra to Co-Market Quantitative Gene-Expression Platform

Luminex and Genospectra have penned a partnership designed to better enable researchers to detect and quantify mRNA in cells, RNAi News’ sister publication GenomeWeb News learned last week.

The agreement, which has not yet been announced, will see Genospectra apply Luminex’ bead-based fluorescence-detection system to its QuantiGene cell-based gene expression-profiling assays, Grant Gibson, director of technical marketing for Luminex, said at the American Society for Cell Biology meeting, held in Washington DC.

Gibson said the collaboration represents “the first application of Luminex’s technology for quantitative gene-expression” applications.

QuantiGene is based on branched DNA technology, in which a molecular probe has many branches of DNA on one end, and an oligonucleotide probe molecule on the other end designed to bind a specific target. For QuantiGene, the target is mRNA in fresh cell lysates, tissue samples, or archived paraffin-embedded tissues.

The branched DNA is currently detected with a chemiluminescent probe, which allows for sensitive detection of minute quantities of RNA without the need to perform PCR.

In combination with Luminex’ platform, Gibson said, the branched DNA would be detected using multi-colored Luminex beads that are subsequently read on the company’s Luminex 100 instrument, which the firms expect will enable highly multiplexed assays and sensitive detection capabilities.

Gibson characterized the relationship as being similar to almost all of Luminex’s other agreements. “We typically don’t sell instruments directly to customers, but instead partner with specific application providers that have validated the platform with their technology.”

Luminex and Genospectra will co-market the product, and Luminex will receive royalty fees stemming from sales of the combined platform, Gibson said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.